Biomerica (BMRA) said Thursday its Fortel prostate-specific antigen screening test has been approved by the United Arab Emirates Ministry of Health and Prevention for detection of prostate cancer.
The company said the test uses a finger-prick blood sample to measure prostate-specific antigen levels.
The company's shares were up more than 227% in recent Thursday trading.
Price: 1.11, Change: +0.77, Percent Change: +227.23